Skip to main content
Terug
Watch Compare

Oncotelic Therapeutics, Inc.

Datakwaliteit: 100%
OTLC
OTC Manufacturing Chemicals
€ 0,03
▼ € 0,01 (-25,00%)
Marktkapitalisatie: 17,70 M
Prijs
€ 0,04
Marktkapitalisatie
17,70 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -55,22% annually over 5 years
Negative free cash flow of -704.008,0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55,22%

Groei

Revenue Growth (5Y)
-55,22%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-19,24%
Boven sectorgemiddelde (-54,01%)
ROIC-5,21%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio0,08
Interest CoverageN/A

Waardering

PE (TTM)
-10,61
Onder sectorgemiddelde (-1,49)
P/B Ratio1,96
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -10,6 -1,5
P/B 2,0 1,6
ROE % -19,2 -54,0
Net Margin % — -41,5
Rev Growth 5Y % -55,2 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 3 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q32023 € 0,00 € 0,00 0,0%
Q22023 € 0,00 -€ 0,02 0,0%
Q42022 € 0,00 -€ 0,01 0,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -55,22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -1,67 M
ROE -19,24% ROA -6,09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -704.008,0
ROIC -5,21% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,08
Interest Coverage N/A Asset Turnover 0,00
Working Capital -18,47 M Tangible Book Value 6,26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,61 Forward P/E N/A
P/B Ratio 1,96 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3,98%
Market Cap 17,70 M Enterprise Value 17,29 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 42,18%
SBC-Adj. FCF -887.750 Growth Momentum 55,22

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2019
Revenue 70.000,0 70.000,0 — 1,74 M —
Net Income -4,52 M -7,90 M 5,09 M -9,39 M -6,64 M
EPS (Diluted) — -0,02 0,01 — —
Gross Profit — — — — —
Operating Income -3,58 M -6,65 M -9,72 M -9,13 M -4,31 M
EBITDA — — — — —
R&D Expenses — 61.143,0 756.910,0 3,66 M 1,37 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 1,04 M 2,97 M 2,00 M 749.602,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 26,68 M 30,01 M 36,12 M 23,61 M 23,66 M
Total Liabilities 19,20 M 18,40 M — — —
Shareholders' Equity 8,25 M 12,13 M 19,41 M 7,96 M 11,77 M
Total Debt 2,42 M 1,77 M 390.050,0 359.262,0 95.000,0
Cash & Equivalents — 170.405,0 241.452,0 568.769,0 474.019,0
Current Assets 134.211,0 271.737,0 303.164,0 627.295,0 615.636,0
Current Liabilities 19,20 M 16,50 M 16,92 M 15,45 M 11,18 M